The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for a ready-diluted formulation of Jetrea, according to a press release from ThromboGenics.Jetrea (ocriplasmin) is approved in the Europe…
Alcon’s Pazeo allergy drop available March 10
ATLANTA – Alcon’s new once daily Pazeo will be commercially available March 10, announced a company representative during a press conference here at SECO.Mike Burns, U.S. allergy brand manager for Alcon, said that Pazeo (olopatadine HCl ophthalmic solution 0.7%), which the FDA approved Jan. 30, will be available to doctors next week.
STAAR names Caren Mason president and CEO
STAAR Surgical has appointed Caren Mason as president and CEO, according to a press release.The appointment is effective immediately. Mason replaces Barry G. Caldwell, who retired March 1.
Fixed-dose combination therapy outperforms prostaglandin alone in reducing diurnal IOP
CORONADO, Calif. — Fixed-dose combination therapy significantly reduced diurnal IOP in patients with ocular hypertension or open-angle glaucoma, according to a poster presented at the American Glaucoma Society meeting.The multicenter randomized study included 88 patients who received brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC) combined with a prostaglandin analogue and 94 patients who received vehicle combined with a prostaglandin analogue.
Oraya’s IRay Radiotherapy system gets CE Mark to treat choroidal metastases
Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung.
Custom sequence testing may accurately define glaucoma severity
CORONADO, Calif. — Custom sequence testing for relative afferent pupillary defect may objectively quantify disease severity compared with standard testing sequence, according to a presentation here.In a poster presented at the American Glaucoma Society meeting, Alice Williams, MD, and colleagues examined 49 patients with glaucoma who underwent relative afferent pupillary defect testing with the Konan RAPDx pupillograph using standard and custom testing sequences.